Cross-Sector entity
Every one of those 1 sits in a single category, clinical-trial. Neurizon is most often covered alongside Massachusetts General Hospital, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Neurizon appears in 1 tracked Cross-Sector story from February 26, 2026.
1 verified story tracked
Last mentioned: Feb 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Neurizon is most often covered alongside Massachusetts General Hospital, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Neurizon appears in 1 tracked Cross-Sector story from February 26, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Neurizon. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected window for preliminary safety and biomarker data review by the trial committee.
Dosing Initiation
First patient dosed with NUZ-001 in the multi-center Phase 2/3 study.
Trial Selection
NUZ-001 selected as a new regimen for the HEALEY ALS Platform Trial.
Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.
Source: sydneysun.com · malaysiasun.com
